Thursday, November 21, 2024
11/21/2024
Project Summary MicroRNAs (miRNAs) are critical post-transcriptional regulators of gene expression in immunity and autoimmunity, although many miRNAs remain poorly characterized. One such miRNA, miRNA-21 (miR-21), is upregulated in systemic lupus erythematosus (SLE) patients and promotes various diseases in mouse models. These include experimental autoimmune encephalomyelitis (EAE), asthma, cancer, and our findings on its role in toll-like receptor 7 (TLR7)-driven SLE in mice. We found that TLR7 overexpressing SLE-prone B6.Sle1bYaa mice deficient in miR-21 (Sle1bYaamiR-21-/-) had reduced germinal center (GC) B cell, T follicular helper (Tfh) cell and plasma cell (PC) responses. These responses in Sle1bYaamiR-21-/- mice were strongly associated with reduced autoantibody, and splenic and bone marrow autoantibody-producing antibody forming cell (AFC) responses. These data substantiate a role for miR-21 in the loss of B cell tolerance and autoimmunity, which necessitates identification of mechanisms (focus of the grant) by which miR-21 promotes autoantibody production and SLE. This will fill gaps in knowledge and may help discover an urgently needed targeted therapy for SLE, a debilitating disease that affects millions of Americans and people world-wide. TLR signaling, especially TLR7, promotes SLE in humans and murine models, and an attractive therapeutic target. TLR7 signaling activates the NF-kB inflammatory signaling pathway. TLR7 upregulates miR-21 expression in B cells which can target the negative regulator of NF-kB signaling, Peli1, although the role of miR-21 in regulating NF- kB signaling in SLE-prone B cells by targeting Peli1 is unknown. Preliminary data showed that B cells from Sle1bYaamiR-21-/- mice have increased Peli1 expression compared to control Sle1bYaa B cells. In addition, previous studies implicated TLR signaling in metabolic reprogramming, primarily through the activation of the PI3K/Akt/mTOR pathway in various immune conditions, although the role of this pathway in TLR7-mediated metabolic reprograming in B cells in SLE is not clear. miR-21 was also shown to regulate the PI3K/Akt/mTOR pathway in various models; however, its role in regulating B cell metabolism in TLR7-driven SLE is not known. Interestingly, our RNA-seq analysis of B cells from a TLR7-induced model showed negatively enriched genes in the PI3K/Akt/mTOR pathway in the absence of miR-21. Additional preliminary data showed increased extracellular acidification (ECAR) and oxygen consumption (OCR) rates in Sle1bYaa B cells overexpressing TLR7 compared to Sle1b B cells, indicating a more energetic phenotype in response to TLR7 signaling. Conversely, Sle1bYaamiR-21-/- B cells exhibited reduced ECAR and OCR compared to Sle1bYaa B cells. We hypothesize that miR-21 promotes TLR7-driven systemic autoimmune responses and SLE disease by regulating TLR7-NF-kB signaling and metabolic reprogramming in B cells. Proposed hypothesis and specific aims will help delineate the mechanism by which miR-21 drives autoimmune responses and lupus nephritis and will inform us whether miR-21 or miR-21 regulated pathway(s) can be a therapeutic target for SLE.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
